Expert Review of Pharmacoeconomics and Outcomes Research

Societal impact of cocaine-associated chest pain: when truth confronts the‘great white lie’
pp. 105-107(3)
Author: Weber, Jim Edward

News in Brief
pp. 109-115(7)

Economic analysis of a self-management asthma plan: is it really effective if further assessed?
pp. 117-119(3)
Author: Antoniu, Sabina A

Salmeterol/fluticasone combination in COPD: is together better?
pp. 121-124(4)
Authors: Antoniu, Sabina A; Mititiuc, Irina

Incorporation of environmental factors into outcomes research
pp. 125-129(5)
Authors: Kuipers, Pim; Foster, Michele M; Bellamy, Nicholas

Item response theory modeling in health outcomes measurement
pp. 131-145(15)
Author: Reeve, Bryce B

Economic evaluations of neuraminidase inhibitors to control influenza
pp. 147-158(12)
Authors: Schwarzinger, Michaël; Lacombe, Karine; Carrat, Fabrice

Pharmacoeconomics of folic acid supplementation for cardiovascular disease prevention
pp. 159-167(9)
Authors: Wrone, Elizabeth; Hornberger, John

Impact of the fourth hurdle on the international pharmaceutical industry
pp. 169-177(9)
Authors: Mullins, C Daniel; Ndiritu, Elizabeth M; Yoder, David M; Shaya, Fadia T; Taylor, Teisha A

Measuring quality of life and utilities in esophageal cancer
pp. 179-188(10)
Authors: McNamee, Paul; Shenfine, Jon; Bond, John

Quality of life outcomes in mental illness: schizophrenia, mood and anxiety disorders
pp. 189-199(11)
Authors: Ritsner, Michael; Kurs, Rena

Costs associated with attention deficit hyperactivity disorder: overview and future projections
pp. 201-210(10)
Authors: Guevara, James P; Mandell, David S